院外心脏骤停患者使用尖端扭转型室速风险药物与可电击心律及自主循环恢复可能性的全国性研究
该研究基于丹麦心脏骤停登记处(2001-2014年)27,481例心脏源性院外心脏骤停成人患者,依据CredibleMeds.org定义尖端扭转型室速(TdP)风险药物,分析骤停前用药与可电击心律及自主循环恢复(ROSC)的关联。结果显示,37%患者在骤停前0-30天使用TdP风险药物,高于骤停前61-90天的33%(p<0.001);最常用药物为西酞普兰(36.1%)和罗红霉素(10.7%)。使用TdP风险药物者年龄更大(75岁 vs 70岁)且合并症更多,其可电击心律可能性(OR=0.63,95%CI 0.58-0.69)和ROSC可能性(OR=0.73,95%CI 0.66-0.80)均降低。
要点
- 心脏源性院外心脏骤停患者中,37%在骤停前0-30天使用TdP风险药物,高于骤停前61-90天的33%(p<0.001)。
- 最常用的TdP风险药物为西酞普兰(36.1%)和罗红霉素(10.7%)。
- 使用TdP风险药物与可电击心律可能性降低相关(OR=0.63,95%CI 0.58-0.69)。
- 使用TdP风险药物与ROSC可能性降低相关(OR=0.73,95%CI 0.66-0.80)。
- 使用TdP风险药物者年龄更大(75岁 vs 70岁)且合并症更多,解读关联时需考虑此差异。
适用人群与场景
- 丹麦心脏骤停登记处(2001-2014年)登记的≥18岁心脏源性院外心脏骤停患者,共27,481例,中位年龄72岁(四分位距62.0-80.0岁)。
诊断标准与关键阈值
- TdP风险药物依据www.CredibleMeds.org定义。
研究设计与关键结果
- 研究为基于丹麦心脏骤停登记处(2001-2014年)的全国性研究,纳入27,481例心脏源性院外心脏骤停成人患者(中位年龄72岁,四分位距62.0-80.0岁)。
- 骤停前0-30天使用TdP风险药物者占37%,骤停前61-90天使用者为33%(p<0.001)。
- 最常用的TdP风险药物为西酞普兰(36.1%)和罗红霉素(10.7%)。
- 使用TdP风险药物者较未使用者年龄更大(75岁 vs 70岁)且合并症更多。
- 使用TdP风险药物与可电击心律可能性降低相关(OR=0.63,95%CI 0.58-0.69)。
- 使用TdP风险药物与ROSC可能性降低相关(OR=0.73,95%CI 0.66-0.80)。
证据类型、等级与局限
- 证据类型:基于丹麦心脏骤停登记处(2001-2014年)的全国性研究,采用多变量logistic回归分析。
- 局限:使用TdP风险药物的患者年龄更大且合并症更多,可能影响关联解读。
对床旁实践的改变
- 在院外心脏骤停全因人群中,骤停前使用TdP风险药物与可电击心律及ROSC可能性降低相关,但使用该类药物者年龄更大且合并症更多。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Treatment with certain drugs can augment the risk of developing malignant arrhythmias (e.g. torsades de pointes [TdP]). Hence, we examined the overall TdP risk drug use before out-of-hospital cardiac arrest (OHCA) and possible association with shockable rhythm and return of spontaneous circulation (ROSC).
METHODS: Patients ≥18 years with an OHCA of cardiac origin from the Danish Cardiac Arrest Registry (2001-2014) and TdP risk drug use according to www.CredibleMeds.org were identified. Factors associated with TdP risk drug use and secondly how use may affect shockable rhythm and ROSC were determined by multivariable logistic regression.
RESULTS: We identified 27,481 patients with an OHCA of cardiac origin (median age: 72 years [interquartile range 62.0, 80.0 years]). A total of 37% were in treatment with TdP risk drugs 0-30 days before OHCA compared with 33% 61-90 days before OHCA (p < 0.001). Most commonly used TdP risk drugs were citalopram (36.1%) and roxithromycin (10.7%). Patients in TdP risk drug treatment were older (75 vs 70 years) and more comorbid compared with those not in treatment. Subsequently, TdP risk drug use was associated with less likelihood of the presenting rhythm being shockable (odds ratio [OR] = 0.63, 95% confidence interval [CI]:0.58-0.69) and ROSC (OR = 0.73, 95% CI:0.66-0.80).
CONCLUSION: TdP risk drug use increased in the time leading up to OHCA and was associated with reduced likelihood of presenting with a shockable rhythm and ROSC in an all-comer OHCA setting. However, patients in TdP risk drug treatment were older and more comorbid than patients not in treatment.
参考来源
- Krøll J, Jespersen CHB, Kristensen SL, et al. Use of torsades de pointes risk drugs among patients with out-of-hospital cardiac arrest and likelihood of shockable rhythm and return of spontaneous circulation: A nationwide study. Resuscitation. 2022. PMID: 35964772. doi:10.1016/j.resuscitation.2022.08.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。